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The clearance of protein-bound solutes by hemofiltration and
hemodiafiltration.
Background. Hemofiltration in the form of continuous ven-
ovenous hemofiltration (CVVH) is increasingly used to treat
acute renal failure. Compared to hemodialysis, hemofiltration
provides high clearances for large solutes but its effect on
protein-bound solutes has been largely ignored.
Methods. Standard clinical systems were used to remove test
solutes from a reservoir containing artificial plasma. Clearances
of the protein-bound solutes phenol red (CPR) and indican (CIN)
were compared to clearances of urea (CUREA) during hemofil-
tration and hemodiafiltration. A mathematical model was de-
veloped to predict clearances from values for plasma flow Qp,
dialysate flow Qd, ultrafiltration rate Qf, filter size and the ex-
tent of solute binding to albumin.
Results. When hemofiltration was performed with Qp 150
mL/min and Qf 17 mL/min, clearance values were CPR 1.0 ±
0.1 mL/min; CIN 3.7 ± 0.5 mL/min; and CUREA 14 ± 1 mL/min.
The clearance of the protein-bound solutes was approximately
equal to the solute-free fraction multiplied by the ultrafiltra-
tion rate corrected for the effect of predilution. Addition of Qd
42 mL/min to provide HDF while Qp remained 150 mL/min
resulted in proportional increases in the clearance of protein-
bound solutes and urea. In contrast, the clearance of protein-
bound solutes relative to urea increased when hemodiafiltra-
tion was performed using a larger filter and increasing Qd to
300 mL/min while Qp was lowered to 50 mL/min. The pattern
of observed results was accurately predicted by mathematical
modeling.
Conclusion. In vitro measurements and mathematical mod-
eling indicate that CVVH provides very limited clearance of
protein-bound solutes. Continuous venous hemodiafiltration
(CVVHDF) increases the clearance of protein-bound solutes
relative to urea only when dialysate flow rate and filter size are
increased above values now commonly employed.
Key words: hemofiltration, hemodiafiltration, CVVH, protein binding.
Received for publication December 21, 2004
and in revised form March 8, 2005
Accepted for publication March 22, 2005
C© 2005 by the International Society of Nephrology
Increasing molecular size limits solute transport by
diffusion more than solute transport by convection.
Henderson et al [1, 2] established that the clearance of
solutes with size ranging from about 500 to 15,000 D
can therefore be increased by employing hemofiltration
instead of hemodialysis. Clinical studies, however, have
so far failed to establish that hemofiltration is more bene-
ficial than hemodialysis over the long term. Hemodialysis
thus remains the predominant modality for end-stage re-
nal disease (ESRD) treatment. Hemofiltration, however,
is increasingly employed in the treatment of acute renal
failure. In this setting, hemofiltration is usually prescribed
as continuous venovenous hemofiltration (CVVH) or
continuous venovenous hemodiafiltration (CVVHDF).
It has been suggested, though not proven, that clearance
of large solutes is particularly important when renal fail-
ure develops in patients with sepsis, shock, or other condi-
tions which precipitate multiorgan failure [3, 4]. Because
they are continuous therapies, CVVH and CVVHDF
may also facilitate control of extracellular fluid volume
in patients with acute renal failure, who often receive
large amounts of intravenous fluid and have low blood
pressure.
Remarkably, most studies of CVVH and CVVHDF
have failed to consider the effect of these treatments
on protein-bound solutes. The kidney clears many sub-
stances which are bound to plasma proteins and in
particular to albumin. Such solutes accumulate in re-
nal failure and there is increasing evidence that some
of them are toxic [5–8]. Protein binding limits con-
vective as well as diffusive transport of solutes across
artificial kidney membranes. We have recently devel-
oped a model which describes the clearance of protein-
bound solutes during hemodialysis [9]. The current study
examined the clearance of protein-bound solutes dur-
ing hemofiltration and hemodiafiltration. A mathemat-
ical model was developed to describe solute clearances
and the predictions of this model were tested in vitro.
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We found that small protein-bound solutes are poorly
cleared by hemofiltration. In particular, our results in-
dicate that CVVH may clear protein-bound solutes less
effectively than intermittent hemodialysis and that the
clearance of such solutes can be increased by adding
dialysis to provide CVVHDF. Dialysate flow rates much
higher than those conventionally used in CVVHDF, how-
ever, are required to make the clearance of protein-
bound solutes approach the clearance of unbound
solutes.
METHODS
Clearance measurements during vitro CVVH and
CVVHDF
CVVH. Clearances of phenol red, indican, urea, and
creatinine were measured during CVVH in vitro. Fluid
representing a patient’s plasma was placed in a continu-
ously stirred 1.0 L reservoir and CVVH was performed
using a Prisma system (Gambro, Lakewood, CO, USA).
The reservoir fluid contained bovine albumin (Sigma
A-7906) (Sigma Chemical Co., St. Louis, MO, USA) at
4.0 g/dL and had electrolyte concentrations which ap-
proximated sodium 149 mEq/L, potassium 4.0 mEq/L,
magnesium 2.0 mEq/L, calcium 2.5 mEq/L, and PO4 47.5
mg/dL with the pH adjusted to 7.4. Reagent phenol red,
indican, urea, and creatinine were added to the reservoir
to provide concentrations of approximately 3.0 mg/dL,
2.0 mg/dL, 120 mg/dL, and 12.0 mg/dL, respectively, at
the beginning of each CVVH run. Replacement fluid con-
tained electrolytes in the same concentrations as reser-
voir fluid but no albumin or test solutes. CVVH was
performed over 150 minutes (four runs) in the predilu-
tion mode using a Prisma M60 Set which includes a 0.6
m2 kidney composed of AN69 hollow fibers with wall
thickness 50 lm. The “plasma” (reservoir fluid) flow rate
set at 150 mL/min and ultrafiltration and replacement
fluid flow rates set equal at 16.7 mL/min. The ultrafiltrate
volume was measured at the end of each experiment.
The free solute fraction was calculated as the average of
the solute concentration in the effluent line divided by the
solute concentration in the reservoir in samples obtained
at 10 and 150 minutes. Additional reservoir fluid samples
were obtained at 0, 10, 30, 60, 90, and 120 minutes for
clearance calculations.
CVVHDF. CVVHDF in vitro was first performed us-
ing the Prisma system with the same kidney and with the
same reservoir and replacement fluids as used in CVVH
experiments. The dialysate had the same composition as
the replacement fluid. The dialysate flow rate was set
at 41.7 mL/min while the plasma flow was again set at
150 mL/min and the ultrafiltration and replacement flow
rates at 16.7 mL/min. The reservoir volume was increased
to 2.0 L and CVVHDF was performed over 75 minutes
(four runs). The total volume of ultrafiltrate combined
with dialysate was measured at the end of each experi-
ment. Batches of albumin-containing fluid were purified
by dialysis for 2 hours before test solutes were added for
clearance experiments. This was done to reduce possi-
ble interference with solute binding to albumin by con-
taminants in the reagent albumin. The free fraction of
each solute was calculated as the average of measure-
ments made at 5 and 75 minutes. Microcon YM-30 tubes
(Millipore, Billerica, MA, USA) were used to obtain ul-
trafiltrate from reservoir fluid for these measurements,
since ultrafiltrate in the effluent line was mixed with
dialysate. Additional reservoir fluid samples were ob-
tained at 0, 5, 15, 30, 45, 60, and 75 minutes for clearance
calculations.
To test the effects of a higher dialysate flow and larger
kidney size, in vitro CVVHDF was performed using a
Fresenius D machine and F6 kidney (Fresenius, Gurnee,
IL, USA). The F6 kidney provides a 1.3 m2 surface area
composed of polysulfone hollow fibers with wall thick-
ness 40 lm. As such, it provides KoA values for vari-
ous solutes which are approximately threefold greater
than those provided by the Prisma M60 set, as further
described in the results below. The dialysate flow rate
for CVVHDF experiments performed with the F6 was
set at 300 mL/min while the plasma flow was set at
55 mL/min and the ultrafiltration and fluid replacement
rates were again set at 16.7 mL/min. CVVHDF was per-
formed over 75 minutes (four runs). Solute free frac-
tions were measured as described above and samples
were collected at 0, 15, 30, 45, 60, and 75 for clearance
calculations.
Chemical assays and clearance calculations. Creati-
nine was measured with a Beckman Creatinine Ana-
lyzer 2 and urea was measured using a commercial kit
(1770-50) (ThermoDMA, Arlington, TX, USA). Indican
was measured by high-performance liquid chromatog-
raphy (HPLC) (Agilent 1100) (Agilent, Palo Alto, CA,
USA). Plasma samples were deproteinized by addition of
900 lL of methanol to 300 lL of plasma. This method
which is derived from that of Lagana et al [10] provided
indican recovery of 102 ± 2% and phenol red recovery of
108 ± 7% (four runs at 1.0 mg/dL and 1.5 mg/dL, respec-
tively). Samples of the resulting supernatant were assayed
by fluorescence detection (excitation 250 nm, emission
410 nm) following processing on a C18 column using gra-
dients of 50 mmol/L ammonium formate and methanol
as described by Lesaffer et al [11]. For CVVH and
CVVHDF, phenol red was assayed using a method mod-
ified from Hirata-Dulas et al [12] as previously described
[9]. For CVVHDF with higher dialysate flow, phenol red
was measured by HPLC using the same protocol as for
indoxyl sulfate but employing ultraviolet absorption at
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433 nm rather than fluorescence for detection. Clear-
ance values were calculated from the best fit slope of log
values for concentrations and from measured reservoir
volume corrected for the volume of samples removed.
Clearance values for various treatments were com-
pared by one-way analysis of variance (ANOVA) with
post hoc least significant difference testing for multiple
comparisons.
Values for KoA for the M60 and F6 filters were deter-
mined in separate experiments in which dialysis was per-
formed without albumin in the reservoir. In these experi-
ments (three for each filter), the Fresenius D machine was
used with the ultrafiltration rate set at zero. For the M60
filter, Qp was set at 200 mL/min and Qd at 300 mL/min
and for the F6 filter, Qp was set at 300 mL/min and Qd
at 500 mL/min. Clearances for urea, creatinine, indican,
and phenol red were measured as the average of the arte-
rial venous (A-V) extraction multiplied by Qp measured
four times over 30 minutes during each experiment. KoA
values for each solute were then obtained from measured
values for clearance, Qp, and Qd using the equation de-
scribed by Michaels [13].
Modeling the effect of protein binding on solute clearance
Hemofiltration. The flux of a solute which is not
protein-bound during hemofiltration can be expressed as:
Js = Jv · (1 − r) · Cp · c (equation 1)
where Jv is the volume flux, r is the reflection coefficient
for the solute, Cp is the solute concentration in plasma,
and c is a factor which relates the solute concentration in
plasma to the solute concentration in plasma water Cpw:
Cpw = c · Cp (equation 2)
This correction factor can be estimated as:
c = 1
1 − h (equation 3)
where h is the plasma protein concentration in g/dL
multiplied by 0.011 [14]. To model the clearance of
protein-bound solutes, we introduced two modifications
in equation 1. First, the model was limited to small solutes
for which r is effectively zero. For modern membranes,
this includes solutes with size less than 2000 D, and thus
includes almost all the protein-bound solutes which have
been shown to accumulate in uremia [7, 15]. Second, it
was assumed that only the portion of a solute not bound
to protein is filtered. The free solute concentration Cpf
available for filtration is thus represented by the follow-
ing:
Cpf = f · Cp. (equation 4)
where f is the fraction of solute which is not bound to
proteins. Solute flux can then be expressed as:
Js = Jv · f · Cp · c (equation 5)
When hemofiltration is performed with replacement
fluid added to the plasma before it enters the kidney,
values for f , Cp, and c must be corrected for the effects
of this “predilution.” The corrected solute concentration
Cp′ is:
C′p =
Cp · Qp
Qp + Qr (equation 6)
and the corrected plasma protein concentration h′ used
to correct c is
h′p =
hp · Qp
Qp + Qr (equation 7)
where Qp is the plasma flow rate and Qr is the replace-
ment fluid addition rate. The effect of predilution on f is
less obvious but while predilution reduces the total solute
concentration and protein concentration in proportion, it
tends to increase the free fraction of a protein-bound so-
lute. The magnitude of this effect can be calculated assum-
ing that solute binding to albumin (or any other binding
protein) is described by an association constant KA such
that:
KA = Cp − CpfCpf · (Calb − Cp + Cpf ) (equation 8)
This being the case, f can be expressed as:
f = 1
1 + (Calb − Cp + Cpf ) · KA (equation 9)
and the value f ′ corrected for predilution is then given by
equation 10 (see Appendix).
The magnitude of this correction, which is hard to ap-
preciate by inspection of equation 10, is illustrated in Fig-
ure 1. It should be noted that the application of equations
8 to 10 to dialysis systems is based on the assumption that
solute binding to protein is rapidly reversible. In using
equation 10 to correct f for the effect of predilution, we
assume that solute can dissociate from protein in the time
it takes for plasma to flow to the kidney from the point in
the circuit where predilution fluid is added. As revealed
by Figure 1, the magnitude of this correction is small for
the Qr/Qp ratios used in our experiments.
During hemofiltration, the free solute concentration
does not change as plasma passes along the kidney. Equa-
tion 5 therefore not only describes local values for flux, ex-
pressed as solute transport and fluid flow per unit length
along the kidney, but also can be used to calculate the
total transport. Solute clearance is then given by:
Cl = Jv · f · c (equation 11)
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Fig. 1. The predicted effect of predilution with a replacement fluid flow
rate (Qr) on the free fraction (f ′) of protein-bound solutes. Curves are
drawn for solutes whose free fractions are 0.10, 0.30, and 0.50 in plasma
before the addition of replacement fluid. f ′ increases as Qr increases
relative to Qp. In clinical practice with Qr less than Qp, the effect is
modest but still large enough so that predilution causes less reduction in
the clearance of protein-bound solutes than in the clearance of unbound
solutes.
with appropriate substitution of f ′ and c′ if predilution is
employed.
Hemodiafiltration. In hemodiafiltration, solute con-
centrations vary along the length of the kidney and local
fluxes must be integrated to obtain total fluxes. For these
calculations, the kidney was considered to have a dimen-
sionless length of unity (0 ≤ x ≤ 1) with the plasma (or
reservoir fluid) inlet and dialysate outlet at x = 0 and
the plasma outlet and dialysate inlet at x = 1, provid-
ing countercurrent flow. The transfer of solute along an
infinitesimal length of the kidney during hemofiltration
with countercurrent flow dialysis must then satisfy the
conservation of mass:
−Js · dx = d (QpCp) = d (QdCd)
(equation 12)
and the transfer of fluid must satisfy the conservation of
volume:
−Jv · dx = dQp = dQd (equation 13)
where Qp is the volumetric flow of plasma, Qd is the
volumetric flow of dialysate, Cp is the solute concentra-
tion in the plasma, and Cd is the solute concentration in
the dialysate. The flux of an unbound solute being trans-
ported by both diffusion and convection can further be
described by the equations 14 to 17 as developed by Vil-
larroel, Klein, and Holland [16] and further elaborated
by Waniewski et al [17]:
Js = −k · (Cpw − Cd) + Jv · (1 − r) · C¯ (equation 14)
where k is the membrane permeability, here expressed
per unit length along the kidney, and
C¯ = Cpw · (1 − u) + Cd · u (equation 15)
with
u = 1
Pe
− 1
exp (Pe) − 1 (equation 16)
where Pe, the Peclet number, is a dimensionless quan-
tity which represents the ratio of convective to diffusive
transport and is given by:
Pe = (1 − r) · Jv
k
(equation 17)
The same modifications used in the case of pure
hemofiltration were again used to adapt these equations
to describe the flux of protein-bound solutes. The model
was restricted to small solutes for which sigma is effec-
tively equal to zero and the effective solute concentration
on the plasma side was assumed to be the unbound solute
concentration:
Cpf = f · Cp (equation 18)
When convection and diffusion are combined, f will
vary along the length of the filter. The local value for f
can be expressed as:
fx =
Cp,x − Calb,x − 1KA +
√(
Calb,x − Cp,x + 1KA
)2
+ 4Cp,xKA
2Cp,x
(equation 19)
where KA is the association constant described in equa-
tion 8 and where Cp,x is the local solute concentration
and Calb,x is the local albumin concentration which is in
turn given by
Calb,x = Calb,0 · Qp,0
Qp,0 −
x∫
0
Jv · dx
(equation 20)
In applying equations 8 and 19, we again assume that
solute binding to protein is rapidly reversible. Specifically,
we assume that the time required for solute to dissoci-
ate from albumin is short in comparison to the time re-
quired for plasma to transit the artificial kidney. In the cur-
rent study, the plasma transit time for experiments with
the M60 kidney was approximately 20 seconds and the
plasma transit time for experiments with the F6 kidney
was approximately 60 seconds. We do not know the rate
constants for the dissociation of phenol red and indican
from albumin. Bilirubin, however, which is much more
tightly bound, can dissociate from plasma albumin in a
fraction of a second [18, 19]. Moreover, the blood transit
time through the native kidney, which effectively removes
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many protein bound solutes, is less than 5 seconds. We
therefore modeled protein bound solute clearance based
on the assumption of rapid dissociation. To the extent
that this assumption is untrue, the real clearance of pro-
tein bound solutes will be less than that predicted by the
model. In the extreme case where no solute dissociates
from albumin as plasma transits the kidney, the clearance
of a protein bound solute would be equal to the clear-
ance of an unbound solute of the same size multiplied
by f .
To determine solute transport using the above equa-
tions, we must first specify the profile of fluid transport
along the kidney. The total fluid transport must add up to
the ultrafiltration rate so that:
Qf =
1∫
0
Jv · dx (equation 21)
For the current model, we assumed that the trans-
membrane hydraulic pressure difference changes linearly
along the kidney and that Jv is proportional to the local
value for transmembrane hydraulic pressure, Px. In this
case, the local value for Jv is:
Jv,x = 2 · Qf ·
[
P0 · (1 − x) + P1 · x
P0 − P1
]
(equation 22)
where P0 is the transmembrane pressure at the plasma
inlet end of the filter and P1 is the transmembrane pres-
sure at the plasma outlet end of the filter.
Using values for f x provided by equations 19 to 22,
equations 12 to 15 can be solved to yield total solute trans-
port in terms of the boundary variables Qp,0, Cp,0, Calb,0,
Qd,1, and Qf and the constants KA and KoA. When predi-
lution is employed, the value Qr is also specified and the
values:
C′p,0 =
Cp,0 · Qp,0
Qp,0 + Qr (equation 23)
C′alb,0 =
Calb,0 · Qp,0
Qp,0 + Qr (equation 24)
and
Q′p,0 = Qp,0 + Qr (equation 25)
are substituted for Qp,0, Cp,0 and Calb,0. For the present
study, KA was calculated from measured values for f , Cp,
and Calb using equations 4 and 8. Predicted values for so-
lute transport were obtained by solving the above equa-
tions using MATLAB (MathWorks, Natick, MA, USA).
It should be noted that for the case of unbound solutes
(KA = 0) and linear variation of Jv along the length
of the filter, Waniewski et al [17] obtained an analytic
solution to these equations. But we did not obtain an
Table 1. Solute clearances during continuous venovenous
hemofiltration (CVVH)
Free fraction Measured Predicted
Solute % clearance mL/min clearance mL/min
Urea 100 ± 8 14 ± 1 16 ± 1
Creatinine 100 ± 3 14 ± 1 16 ± 1
Indican 25 ± 3a 3.7 ± 0.5a 4.3 ± 0.6a
Phenol red 8.1 ± 1.0a,b 1.0 ± 0.1a,b 1.4 ± 0.2a,b
Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained with Qp ≈ 150 mL/min, Qr ≈ 17 mL/min,
and Qf ≈ 17 mL/mn.
aP < 0.05 vs. value for urea; bP < 0.05 vs value for indican.
analytic solution which described the transport of
protein-bound solutes. We are thus unable to provide a
formula for clearance during CVVHDF analogous to the
formula provided by equation 11 for CVVH or by the
equations of Michaels [13] for hemodialysis using coun-
tercurrent flow.
Input values of the model described above include the
transmembrane pressures P0 and P1 which are not
routinely measured in clinical practice. In modeling clin-
ical CVVHDF, however, the simplifying assumption of
a uniform value for P along the length of the filter
can be employed without introducing significant error.
For instance, in a separate experiment in which an ad-
ditional pressure transducer was added to the clinical
system, we found that when CVVHDF was performed
with the M60 at the flows used in this study, P0 was
88 mm Hg and P1 was 62 mm Hg. Use of a constant
P value instead of these measured values produced
changes in predicted solute clearance values of less than
1%. When CVVHDF was performed with the F6 and the
flows used in this study, measured values for P0 and
P1 were 17 mm Hg and was 15 mm Hg. Use of con-
stant P values instead of these measured values again
produced changes in predicted solute clearance values of
less than 1%. In general, variation of P along the fil-
ter will affect clearances only when rapid ultrafiltration
is combined with efficient dialysis, and the effect of P
variation on clearance will diminish as solute binding in-
creases. It should be noted that in such cases the pressure
drop along the kidney may not be linear, as ultrafiltration
simultaneously decreases blood flow and increases blood
viscosity.
RESULTS
Clearances measured during CVVH in vitro are sum-
marized in Table 1. Clearance values for the unbound
solutes urea and creatinine averaged 14 ± 1 mL/min.
Clearance values for the protein bound solutes were
much lower, averaging 3.7 ± 0.5 mL/min for indican and
1.0 ± 0.1 mL/min for phenol red. The measured values
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Table 2. Solute clearances during continous venovenous
hemodiafiltration (CVVHDF) with dialysate flow less than plasma
flow
Free Fraction Measured Predicted
Solute % clearance mL/min clearance mL/min
Urea 100 ± 1 45 ± 2a 52 ± 2
Creatinine 101 ± 1 42 ± 3a 51 ± 2
Indican 18 ± 5b 10 ± 2a,b 9 ± 2b
Phenol red 6.4 ± 0.9b,c 2.7 ± 0.3a,b,c 2.9 ± 0.4b,c
Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained using an M60 filter with Qp ≈ 150 mL/min,
Qd ≈ 42 mL/min, Qr ≈ 17 mL/min, and Qf ≈ 17 mL/mn.
aP < 0.05 vs measured clearance during in vitro continuous venovenous
hyperfiltration (CVVH).
bP < 0.05 vs. value for urea.
cP < 0.05 vs. value for indican.
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Fig. 2. Solute concentrations along the length of a dialyzer during con-
tinous venovenous hemodiafiltration (CVVHDF) with Qd < Qp. In
each panel, dialyzer length is on the horizontal axis with the plasma in-
let and dialysate plus ultrafiltrate outlet at the left (x = 0) and the plasma
outlet and dialysate inlet at the right (x = 1). Solute concentration is
on the vertical axis. The total plasma solute concentration (red line) is
set equal to 1.0 prior to predilution and the dialysate solute concen-
tration (blue line) is set equal to 0.0 at the dialysate inlet. When there
is protein binding, the concentration of unbound solute is depicted by
the broken red line. The gradient driving diffusion is indicated by the
shaded area. The top panel depicts the clearance of an unbound solute
during CVVHDF performed with Qp ≈ 150 mL/min, Qf ≈ 17 mL/min,
and Qr ≈ 17 mL/min predilution, Qd ≈ 42 mL/min, and KoA ≈ 150
mL/min. The solute concentration in the slowly flowing dialysate plus
ultrafiltrate stream approaches the solute concentration in the plasma
entering the filter and the clearance is 49 mL/min. This is close to the
theoretic maximum of 53 mL/min imposed by the sum of Qd and Qf
corrected for the effect of predilution. The bottom panel depicts the
clearance of a solute which is 90% bound to plasma protein. The so-
lute concentration in the dialysate plus ultrafiltrate stream is limited
by the free solute concentration in the plasma entering the filter and
the clearance is 5.5 mL/min. The value is slightly higher than 10% of
the unbound solute clearance because predilution increases the solute
free fraction from 10% to 11%. The relative magnitude of the solute
clearances is reflected by the size of the arrows on the left of the figure.
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Fig. 3. The predicted effect of KoA on solute clearances during con-
tinous venovenous hemodiafiltration (CVVHDF) with Qd < Qp. The
conditions represented are similar to those of our experiments with
Qd ≈ 42 mL/min and Qf ≈ 17 mL/min except that the small effect
of predilution is omitted for simplicity. As KoA increases, clearance of
an unbound solute (green line) approaches the theoretic maximum of
Qd plus Qf and the clearance of a solute which is 90% protein bound
(purple line) approaches the theoretic maximum of 10% of Qd plus Qf.
Near maximal clearance values are obtained with small filters as long
as Qd is low.
were close to the values predicted by equation 11. Essen-
tially, the predicted clearance rate for unbound solutes is
the ultrafiltration rate corrected for the effect of predi-
lution. The predicted clearance rate for bound solutes
is obtained by multiplying this value by the plasma free
fraction, with a further correction for the effect of predi-
lution on the free fraction as described in the Methods
section (equations 10 and 11) and Figure 1.
Clearances measured during CVVHDF performed
with the dialysate flow lower than the plasma flow are
summarized in Table 2. These experiments were per-
formed using the maximal dialysate flow rate attainable
with a commonly used CVVHDF system. The clearance
rates of all solutes were significantly increased in com-
parison with values obtained during CVVH alone. Mea-
sured clearance values for the unbound solutes urea and
creatinine averaged 45 ± 2 mL/min and 42 ± 3 mL/min,
respectively. Clearance values for the bound solutes also
increased but remained much lower than those for the un-
bound solutes. Overall, the proportional increase in clear-
ance observed with the addition of dialysate to CVVH
was similar for the unbound and bound solutes, and av-
eraged approximately threefold.
The finding that superimposing dialysis with Qd < Qp
on hemofiltration increases the clearances of unbound
and bound solutes in similar proportion is in accord
with the predictions of the model. With dialysate flow
much lower than plasma flow and with adequate mem-
brane permeability, the model predicts that the solute
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Fig. 4. Solute concentrations along the length of a dialyzer during con-
tinuous venovenous hemodiafiltration (CVVHDF) with Qd > Qp. The
plasma total solute concentration (red line) and free solute concentra-
tion (broken red line) and dialysate solute concentration (blue line)
are depicted as in Figure 2. The top panel depicts the clearance of an
unbound solute in CVVHDF performed with Qp ≈ 50 mL/min, Qf ≈
17 mL/min, and Qr ≈ 17 mL/min predilution, Qd ≈ 300 mL/min, and
KoA ≈ 600 mL/min. Solute is rapidly removed from the plasma and the
calculated clearance is 50 mL/min, which is the limiting value imposed
by the plasma flow. The bottom panel depicts the clearance of a solute
which is 90% bound to plasma protein while other parameters remain
the same. The gradient driving solute diffusion into the dialysate plus
ultrafiltrate stream is reduced by protein binding. Transport continues
along the length of the dialyzer because the increased dialysate flow
keeps the level in the dialysate plus ultrafiltrate compartment lower
than the free level in the plasma. The bound solute clearance of 23
mL/min is almost half the clearance of the unbound solute, and could
be made to approach even closer to the plasma flow by further increas-
ing Qd and KoA.
concentrations in the mix of dialysate and ultrafiltrate
leaving the kidney will be nearly equal to the free solute
concentrations in the plasma entering the kidney, as il-
lustrated in Figure 2. The clearance of each solute will
thus approach the sum of the dialysate flow and ultrafil-
tration rates multiplied by the free solute concentration
at the kidney inlet. Solute clearances will fall below this
theoretic maximum if the kidney has a low mass transfer
area coefficient, as shown in Figure 3. Dialysis experi-
ments performed without albumin yielded KoA values
for the M60 set of 186 ± 12 for urea, 106 ± 6 for crea-
tinine, 108 ± 10 for indican, and 61 ± 6 for phenol red.
In our CVVHDF experiments with Qd < Qp, values for
KoA were thus greater than Qd. When this is the case,
as further shown in Figure 3, an increase in kidney size
would not significantly increase solute clearances. When
Qd < Qp, changes in Qp will likewise have little effect on
clearance. Our model predicts, for example, that reducing
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Fig. 5. The predicted effect of increasing Qd and KoA on solute clear-
ances during continuous venovenous hemodiafiltration (CVVHDF).
The curves illustrate the clearance of an unbound solute (green line)
and a solute which is 90% protein bound (purple line) as Qd and KoA
are increased with KoA equal to twice Qd at every point. The clearance
of both unbound and bound solutes is limited by the plasma flow rate,
Qp. But raising solute clearance to any desired fraction of Qp requires
much larger values of Qd and KoA when the solute is protein bound
than when the solute is unbound. The ultrafiltration rate Qf, which is set
at one third of Qp in this figure, has a significant effect on the clearance
of small solutes only when Qd and KoA are relatively low.
Qp from 150 to 75 mL/min while Qd is maintained at 42
mL/min would reduce the clearance of urea by less than
15% and the clearance of indican and phenol red by less
than 5%.
Having found that superimposing dialysis with Qd <
Qp on hemofiltration increases the clearance of bound
and unbound solutes in nearly equal proportion, we
sought a means to preferentially increase the clearance
of bound solutes. The model predicts that this can be ac-
complished by increasing the dialysate flow above the
plasma flow as long as membrane permeability is ade-
quate. The results of in vitro CVVHDF experiments per-
formed to test this prediction are summarized in Table
3. The measured clearances of urea and creatinine, 52
± 3 mL/min and 54 ± 3 mL/min, respectively, were only
slightly greater than observed in the previous experiment.
But the measured clearances of indican and phenol red,
31 ± 2 mL/min and 10.2 ± 0.4 mL/min, respectively, were
increased threefold. The ratio of bound to unbound so-
lute clearances was thus greatly increased, in accord with
the predictions of the model.
The solute concentration profiles associated with the
increased clearance of bound solute when Qd is greater
than Qp are depicted in Figure 4. Increasing the dialysate
flow above the plasma flow reduces solute concentrations
in the dialysate plus ultrafiltrate compartment. The un-
bound solute diffuses readily into the large quantity of
dialysate plus ultrafiltrate, and its concentration rapidly
approaches zero as the plasma flows through the kid-
ney. Thus, for the unbound solute, transport is practi-
cally complete in the early part of the kidney and the
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Table 3. Solute clearances during continous venovenous
hemodiafiltration (CVVHDF) with plasma flow less than dialysate
flow
Free Measured Predicted
Solute fraction % clearance mL/min clearance mL/min
Urea 105 ± 1 52 ± 3a 53 ± 1
Creatinine 99 ± 6 54 ± 3a 53 ± 1
Indican 16 ± 1b 31 ± 2a,b 27 ± 1b
Phenol red 5.8 ± 0.7b,c 10.2 ± 0.4a,b,c 9.0 ± 0.9b,c
Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained using an F6 filter with Qp ≈ 55 mL/min, Qd
≈ 300 mL/min, Qr ≈ 17 mL/min, and Qf ≈ 17 mL/min.
aP < 0.05 vs. measured clearance during in vitro continous venovenous
hemofiltration (CVVH) and CVVHDF with dialysate flow less than plasma flow.
bP < 0.05 vs. value for urea.
cP < 0.05 vs. value for indican.
clearance approaches the plasma flow rate. The concen-
tration profile for the protein-bound solute is different.
The gradient driving diffusion is reduced by protein bind-
ing even though the high dialysate flow keeps the solute
concentration in the combined dialysate plus ultrafiltrate
low. So the rate of solute transfer in the early part of the
kidney is much lower than for the unbound solute. But
as free solute diffuses through the membrane, bound so-
lute dissociates from protein, replenishing the low free so-
lute concentration available for diffusion and convection.
The total concentration and the free concentration of the
protein-bound solute fall gradually together as transport
continues along the length of the kidney. In contrast to
the result obtained when dialysate flow is only a fraction
of plasma flow, the clearance of the protein-bound solute
can now exceed the clearance of the unbound solute mul-
tiplied by the free fraction of the bound solute. Again, we
are assuming that the time required for solute to disso-
ciate from the binding protein is short compared to the
transit time of plasma through the kidney.
To obtain a high relative clearance of protein-bound
solutes during CVVHDF requires an increase in KoA as
well as in Qd. Dialysis experiments performed without
albumin yielded KoA values for the F6 dialyzer of 549 ±
30 mL/min for urea, 353 ± 24 mL/min for creatinine, 371
± 17 mL/min for indican, and 221 ± 13 mL/min for phenol
red. In our CVVHDF experiments with Qd > Qp, esti-
mated KoAs were thus of approximately the same mag-
nitude as Qd. Theoretically, as long as KoA is adequate,
the clearance of even a tightly bound solute can be made
to increase arbitrarily close to the limiting value imposed
by the plasma flow, as illustrated in Figure 5. The figure
shows modeled clearance values for an unbound solute
and a protein-bound solute as Qd is increased from zero
(pure ultrafiltration) to greatly exceed Qp while the Qf
remains constant and KoA increases with Qd. For an un-
bound solute, the clearance at Qd = 0 mL/min is equal
to Qf, and the clearance at low values for Qd is close to
the sum of Qf and Qd, as has been previously described
[20–22]. As Qf is increased, the clearance of the unbound
solute falls below the sum of Qf and Qd but still rapidly
rises to approach Qp. The clearance profile for a protein-
bound solute is much different. For low values of Qd, the
clearance is close to the clearance of the unbound so-
lute multiplied by the fraction of the bound solute which
is free in plasma. As Qd increases, the clearance of the
bound solute increases more gradually than the clearance
of an unbound solute, but keeps rising after the clearance
of the unbound solute has reached the limiting value of
Qp. It should be noted that with high dialysate flow, the
transport of small solutes is accomplished largely by dif-
fusion, and turning ultrafiltration on and off has only a
minor effect on solute clearance.
DISCUSSION
The first aim of this study was to assess the clearance of
protein-bound small solutes during hemofiltration. Re-
sults showed that for a given protein-bound solute, the
clearance is approximately the ultrafiltration rate mul-
tiplied by the free solute fraction, corrected as neces-
sary for the effects of predilution on solute concentration.
Protein-bound solutes are thus poorly cleared by conven-
tional CVVH. For instance, with an ultrafiltration rate of
30 mL/min, the predicted clearance of a solute which is
90% protein bound is only 3 mL/min using postdilution
and slightly less than 3 mL/min using predilution.
The limitation imposed by protein-binding on solute
clearance during hemofiltration is not hard to understand,
but has received little attention. Hemofiltration was
developed to improve the clearance of solutes whose
diffusive transport during dialysis is limited by size [2].
Advocates of hemofiltration suggest that it is “more phys-
iologic” than dialysis because it removes solutes by a pro-
cess analogous to glomerular filtration [23, 24]. In this
view, the infusion of replacement fluid takes the place of
tubular reabsorptive function. But the absence of tubu-
lar secretory function, by which the normal kidney clears
protein-bound solutes, is ignored.
The second aim of this study was to assess the clear-
ance of protein-bound small solutes during hemodiafil-
tration when dialysis is superimposed on hemofiltration.
We found that as long as dialysate flow is low compared to
plasma flow, the superimposition of dialysis on hemofil-
tration increases the clearances of unbound and protein-
bound solutes in proportion, with the clearance rate for a
given solute being approximately the free solute fraction
multiplied by the sum of the ultrafiltration and dialysate
flow rates. The hemodiafiltration prescriptions now com-
monly employed in the treatment of acute renal failure
thus do not provide greater relative clearance of protein-
bound solutes than pure hemofiltration.
The final aim of this study was to identify means by
which the clearance of protein- bound solutes can be
increased relative to the clearance of unbound solutes.
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Table 4. Modeled solute clearances during renal replacement therapy
Conventional CVVH CVVH CVVHDF CVVHDF Low efficiency Low efficiency
Modality hemodialysis low Qf high Qf low Qd high Qd hemodialysis hemodialysis
Qb mL/min 350 150 150 150 50 200 100
Qf mL/min 24 20 40 20 20 4 4
Qr mL/min 0 18 38 18 18 0 0
Qd mL/min 600 0 0 20 300 100 200
KoAurea mL/min 800 200 200 200 600 600 600
Clurea mL/min 270 19 34 38 45 100 90
Cl90%−bound mL/min 46 2.0 4.2 4.2 21 11 20
Abbreviations are: CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous hemodiafiltraton. Modeled clearance values for urea (Clurea)
and a hypothetical solute of the same size which is 90% protein-bound (Cl90%−bound) during renal replacement therapy. The various prescriptions would provide the
same net ultrafiltration if conventional hemodialysis was applied every other day and the other treatments were provided daily. The hematocrit was assumed to be 33%
in each case.
We found that this can be accomplished by increasing
the dialysate flow rate while restricting the plasma flow
rate during hemodiafiltration. Indeed, by adequately in-
creasing the dialysate flow, the clearance of small protein-
bound solutes can be increased arbitrarily close to the
clearance of small unbound solutes as long as kidney size
is adequate. It should be noted that in current practice,
when the dialysate flow exceeds the plasma flow, it also
exceeds the ultrafiltration rate. In this setting, the contri-
bution of ultrafiltration to the transport of protein-bound
solutes is relatively small, and the clearance of protein-
bound solutes is only slightly higher than that achieved by
dialysis alone. The clearance of large solutes, in contrast,
will still depend heavily on ultrafiltration.
The current model also reveals one alternate theoret-
ical means to increase the clearance of protein-bound
solutes. As shown in Figure 1, if we assume solutes can
rapidly dissociate from their binding proteins, the bound
fractions will fall as the rate of predilution rises, and solute
clearances can be increased during pure ultrafiltration by
using predilution and increasing the replacement and ul-
trafiltration rates to greatly exceed the plasma flow. Be-
cause replacement fluid is more expensive than dialysate,
however, this treatment would not be cost effective.
Solute clearances have the same dependence on
plasma and dialysate flows during intermittent and
continuous treatment. But hemofiltration and hemodi-
afiltration are most often prescribed continuously for
the treatment of acute renal failure. Currently employed
CVVH and CVVHDF regimens provide greater clear-
ances of large solutes than intermittent hemodialysis
while providing equal or greater clearances of urea, de-
pending on the exact prescription [21, 25–27]. The current
study suggests that in contrast, CVVH and CVVHDF
may provide relatively low clearances of protein-bound
solutes, as summarized in Table 4. The table presents
clearance values for urea and a hypothetical solute PBS
which is 90% bound to albumin. The clearance values
have been calculated using the model described in the
current study with the urea clearances corrected for the
transport of urea out of red cells as described by Depner
[28]. Intermittent hemodialysis with Qb ≈ 350 mL/min
and Qd ≈ 600 mL/min is predicted to provide a PBS
clearance of ≈ 42 mL/min while CVVH with Qf ≈ 17
mL/min is predicted to provide a PBS clearance of only
1.5 mL/min. Because volumes of distribution for protein-
bound solutes have not been measured, it is not pos-
sible to compare the theoretic effects of intermittent
and continuous treatment on plasma solute concentra-
tions. Lesaffer et al [11] found that the concentrations
of two solutes which are approximately 90% albumin
bound fell much less than the concentration of urea dur-
ing hemodialysis treatment in vivo. If albumin-bound so-
lutes were restricted largely to the plasma space, their
concentration would fall rapidly during dialysis despite
the restriction imposed on clearance by albumin binding.
The finding of Lesaffer et al [11] thus suggests that the
volumes of distribution for protein-bound solutes may
be considerably larger than the plasma volume, in which
case CVVH with Qf ≈ 17 mL/min would lower plasma
protein-bound solute concentrations less effectively than
intermittent dialysis performed 4 hours every other day.
As further shown in Table 4, the predicted clearance of
unbound and bound solutes during CVVH treatment will
increase approximately in proportion if the ultrafiltration
rate is increased to the recently recommended level of 35
mL/kg/hour, or about 40 mL/min for an averaged size
person [29]. Similar clearances of bound solutes would
be achieved by shifting to CVVHDF and providing the
same total amount of fluid with half used as replacement
fluid and half used as dialysate.
The restriction on the clearance of bound solutes rel-
ative to unbound solutes can be overcome only by using
higher dialysate flows and larger kidneys than are now
commonly employed for CVVHDF, as further summa-
rized in Table 4. When high dialysate flows are employed,
the clearance of small molecules is accomplished almost
entirely by diffusion and ultrafiltration serves only to in-
crease the clearance of large molecules. The predicted
dependence of protein-bound solute clearances on
dialysate flow and kidney size will be the same when in-
termittent treatment is prescribed. Recent studies have
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described the treatment of acute renal failure using
hemodialysis for 8 to 12 hours daily [30, 31]. These “low
efficiency” regimens often restrict the clearance of urea
and other small unbound solutes by limiting the dialysate
flow rate [31]. Our model predicts that the clearance of
protein-bound solutes would be greater if the clearance
of unbound solutes were restricted by limiting the blood
flow rate while maintaining a higher dialysate flow. For
instance, as summarized in Table 4, the predicted clear-
ance of a 90% protein-bound solute would be 10 mL/min
during low efficiency dialysis with Qb ≈200 mL/min and
Qd ≈ 100 mL/min and 18 mL/min during low efficiency
dialysis with Qb ≈ 100 mL/min and Qd ≈ 200 mL/min,
while both regimens would provide nearly the same urea
clearance.
Several limitations of the current study should be ac-
knowledged. We have assumed that solute dissociation
from albumin is rapid compared to the plasma transit time
through the kidney. The efficient extraction of protein
bound solutes by the kidney suggests that this is indeed of-
ten the case, but measured dissociation rates are generally
not available. Our model also assumes thorough solute
mixing in both the plasma and the ultrafiltrate/dialysate
compartments. To the extent that mixing is not complete,
the assumption that kidneys can be characterized by sin-
gle KoA values is not justified, and measured clearances
will fall below predicted values. The magnitude of this
error may be expected to increase when kidneys are em-
ployed using flow rates for which they were not designed.
In addition, the KoA values we used in modeling were
obtained from measurements of clearance from albumin-
free solutions, and may have exceeded the KoA values
obtained when kidneys were perfused with 4% albumin
[32, 33].
Despite these limitations, the current model accurately
predicted the extent to which clearances of protein-
bound solutes are restricted during hemofiltration and
hemodiafiltration in vitro. Further studies are obviously
required to determine whether the model predicts the
behavior of protein-bound solutes in vivo. It should be
noted that numerous solutes may compete for protein
binding sites in uremic patients. The fractions of vari-
ous solutes which are bound to protein may therefore
increase unpredictably as solute concentrations fall dur-
ing treatment. In general, clearance values would be ex-
pected to decline as protein-binding increases, but this
requires testing in practice. A further interesting possi-
bility is that some uremic solutes bind to other blood
constituents such as lipids or red cells in vivo. If binding
is rapidly reversible, such solutes, like protein-bound so-
lutes, might be effectively cleared by the normal kidney
but poorly cleared by hemofiltration.
To the extent that they apply in vivo, our findings sug-
gest that conventional CVVH and CVVHDF regimens
provide limited clearance of protein-bound solutes. Clin-
ical studies, as far as we are aware, have yet to exam-
ine this issue. A recent clinical study has shown that ad-
dition of hemofiltration at rates of 5 to 15 L per hour
increases p-cresol clearance in patients receiving inter-
mittent hemodialysis [34]. The current model predicts this
effect, but suggests that increases of the same magnitude
could be more easily achieved by increasing dialysate
flow rate and dialyzer size. A broader question is whether
the clearance of protein-bound solutes is clinically impor-
tant. Increasing evidence, however, links protein-bound
solutes to uremic toxicity [6]. Limited clearance of such
solutes could explain, at least in part, why the improved
clearance of large solutes obtained with ultrafiltration
based therapies has so far not been associated with a dis-
cernable improvement in patient outcome [35–37]. Clin-
ical studies of modalities which increase protein-bound
solute clearances will be required to address this ques-
tion.
APPENDIX
f ′ =
c(c − 1)(1 − f ) − (q + 1)c f (c f − c + 1) + √[c(1 − c)(1 − f ) + (q + 1)c f (c f − c + 1)]2 + 4(q + 1)c3 f (c f − c + 1)(1 − f )
2c2 (1 − f )
(equation 10)
where c = Cp/Calb and q = Qr/Qp.
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